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Abstract
The androgen receptor (AR) is the dominant growth factor in prostate cancer (PCa).
Therefore, understanding how ARs regulate the human transcriptome is of paramount
importance. The early effects of castration on human PCa have not previously been
studied 27 patients medically castrated with degarelix 7 d before radical prostatec-
tomy.We usedmass spectrometry, immunohistochemistry, and gene expression array
(validated by reverse transcription-polymerase chain reaction) to compare resected
tumour with matched, controlled, untreated PCa tissue. All patients had levels of
serum androgen, with reduced levels of intraprostatic androgen at prostatectomy.
We observed differential expression of known androgen-regulated genes (TMPRSS2,
KLK3, CAMKK2, FKBP5). We identiﬁed 749 genes downregulated and 908 genes upre-
gulated following castration. AR regulation of a-methylacyl-CoA racemase expression
and three other genes (FAM129A, RAB27A, and KIAA0101) was conﬁrmed. Upregulation
of oestrogen receptor 1 (ESR1) expression was observed in malignant epithelia and
was associated with differential expression of ESR1-regulated genes and correlated
with proliferation (Ki-67 expression).
Patient summary: This ﬁrst-in-man study deﬁnes the rapid gene expression changes
taking place in prostate cancer (PCa) following castration. Expression levels of the genes
that the androgen receptor regulates are predictive of treatment outcome. Upregulation
of oestrogen receptor 1 is a mechanism by which PCa cells may survive despite
castration.
# 2015 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
* Corresponding author. Cancer Research UK Cambridge Institute, Li Ka Shing Centre, RobinsonWay,
Cambridge, CB2 0RE, United Kingdom. Tel. +44 0 1223 769500; Fax: +44 0 1223 769007.
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Prostate cancer (PCa) is the second most common cause of
cancer death in men in the developed world [1]. The
androgen receptor (AR) controls PCa growth. Previously,
studiesof the long-termeffects (>3mo)ofmedical castration
have demonstrated differing transcriptional response fol-
lowing luteinising hormone-releasing hormone (LHRH)
analogue and antiandrogens [2] and have implicated Wnt/
b-cateninsignalling incastration-resistantPCa [3].Weuseda
new drug called degarelix to rapidly decrease testosterone
levels and inform the early in vivo response of human PCa to
castration.
1. Patients and methods
1.1. Study approval
We obtained full ethics approval for all elements of studies NCT01852864
(REC ref:11/H0311/2) and NCT00967889 (REC ref:01/4/061).
1.2. Clinical sample collection
Twenty-seven patients with high-risk PCa (according to the D’Amico
classiﬁcation) [4] were administered 240 mg subcutaneous degarelix
(donated by Ferring Pharmaceuticals Inc, Parsippany, NJ, USA) 7 d before
radical prostatectomy (RP) (Supplementary Fig. 1a). These patients were
matched for risk factors (age, serum prostate-speciﬁc antigen, tumour
grade and stage) with 20 patients undergoing RP without neoadjuvant
degarelix (Supplementary Table 1). Study and control patients under-
went surgery contemporaneously using standard operative technique,
with similar ischemic time before sampling as described [5]. Serum
samples were obtained at 8 AM prior to surgery.
1.3. Assay of androgen levels in body fluids and tissue
Fresh frozen prostate cores were homogenised, and steroids were
extracted and quantiﬁed by liquid chromatography coupled with
tandem mass spectrometry.
1.4. Gene expression profiling
We hybridised mRNA onto Illumina HumanHT-12 v4 Expression
BeadChips (Illumina, San Diego, CA, USA).
1.5. Accession numbers
Study data are deposited in the National Center for Biotechnology
Information Gene Expression Omnibus under accession number
GSE72920. Expression data were validated for known AR-regulated genes
(KLK3, FASN), genes found to be AR regulated in our expression data with
known AR binding sites in promoter regions [6] (FAM129A, KIAA0101,
RAB27A) and genes of biological importance (AMACR, ESR1, cyclin D1) by
reverse transcription-polymerase chain reaction (RT-PCR) and immuno-
histochemistry (IHC).
1.6. Quantitative real-time polymerase chain reaction
We performed RT-PCR in triplicate using SYBR Green and the 7900HT
Real-Time PCR System (Applied Biosystems, Foster City, CA, USA).
1.7. Human tissue microarray construction and
immunohistochemistry
PCa samples (index lesion) from 27 patients were identiﬁed on
the haematoxylin and eosin–stained sections from formalin-ﬁxed
parafﬁn–embedded RP specimens and marked (A.W.). Triplicate 2-
mm tumour cores were taken from these areas and re-embedded in
human tissue microarray (TMA) parafﬁn blocks.
We used a BOND-III automated stainer (Leica Biosystems, Buffalo
Grove, IL, USA) and Bond Polymer ReﬁneDetection Kit (Leica Biosystems)
for IHC. Scoring was by two blinded observers (including A.W.) until
consensus was reached. Staining intensity was classiﬁed as 0 (none),
1 (weak), 2 (moderate), and 3 (high). For nuclear staining (ESR1, Ki-67,
and CCND1), we used the followingmodiﬁed scoring systems to quantify
the number of moderately or intensely staining nuclei as a proportion of
all the malignant epithelial cells: ESR1 and CCND1 staining (0, no
intensely staining positive nuclei; 1, 0.1–10% intensely stained nuclei per
core; 2, 10–20% intensely staining nuclei per core; 3,>20% stained nuclei
per core) and Ki-67 staining (0, no positive nuclei; 1, 1–5% positive
nuclei; 2, 5–10% positive nuclei; 3, >10% positive nuclei).
1.8. Statistical analysis
All data are quoted as median plus or minus interquartile range, and
p values <0.05 were considered signiﬁcant. We use the paired t test for
paired data; for unpaired data, we used an unpaired t test for parametric
data and the Mann-Whitney test for nonparametric data. For TMA IHC
scoring analysis, we computed the mean intensities for each sample and
performed a Mann-Whitney test.
1.9. Gene set enrichment analysis
We used Gene Set Enrichment Analysis (GSEA) version 2.0.14 (The Broad
Institute, Cambridge, MA, USA). We used the Reactome version 3.0 data-
base to analyse differentially expressed genes (DEGs) following castration
for enrichment of predeﬁned gene sets. Using the JASPAR database in the
PscanWeb interface (version 1.3), we analysed 500 bases upstream of the
top 500 DEGs for enriched transcription factor binding sites (Fig. 2C).
2. Results
We saw no differences in the tumour or patient character-
istics of the study and control cohorts (Supplementary
Table 1). We saw a rapid decrease in the serum testosterone
at 7 d after degarelix administration in all treated patients
(11.73 5.08 vs 1.19  0.63 nmol/l) (Supplementary Fig. 1B),
paralleled by a decrease in intratumoural androgens (Supple-
mentary Fig. 1C). We identified 749 genes downregulated and
908 genes upregulated in response to castration. Expression
levels of known AR-regulated genes—including TMPRSS2,
FKBP5, KLK3, and FASN—were among those most strongly
affected by treatment (Supplementary Table 2 and 3). We
validated differential expression for eight genes by RT-PCR and
IHC (Fig. 1B and 1C).
Degarelix treatment decreased nuclear expression of
proliferation marker Ki-67 protein and cell cycle progres-
sion (expression of nuclear CCND1) (Fig. 1B and 1C). We
observed and validated decreased expression of three genes
with limited evidence of AR regulation but with AR binding
sites in their promoter regions (RAB27A, KIAA0101, and
FAM129A) following degarelix treatment (Fig. 1A–1C)
2.1. ESR1 expression is upregulated in malignant epithelia, is
pro-proliferative, and is associated with transcription of known
ESR1 target genes
Degarelix treatment upregulated ESR1 mRNA (Fig. 2A).
Using GSEA, we demonstrated enrichment of genes that had
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Fig. 1 – Degarelix treatment regulates expression of known androgen receptor (AR)–regulated genes and genes not previously identified as AR regulated.
(A) Messenger RNA expression levels of known AR-regulated genes PSA and FASN as well as putative AR-regulated genes AMACR, FAM129A, RAB27A, and
KIAA0101 were decreased in degarelix-treated (+) prostate cancer (PCa) samples compared with untreated (S) samples. (B) Representative
immunohistochemistry (IHC) images of PCa samples from degarelix-treated and untreated patients. Inlay = T2 magnification. Scale bars = 250 mm.
(C) Bar chart to show the distribution of staining intensity of a tissue microarray made up of PCa samples from untreated (S) and degarelix-treated (+)
patients stained by IHC (0 [no staining] to 3 [intense staining]; samples in triplicate; sample sizes [n] evaluated in each analysis include the number of
subjects [20 or 27] times 3 minus missing or damaged samples; staining intensity 0 [none] to 3 [strong]). Mean intensities from replicate samples for each
patient were used to calculate statistical significance when comparing treated and untreated groups (Mann-Whitney test).
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an ESR1 binding motif (Fig. 2B) [7] within the promoter
region and genes known to be involved in ESR1 signalling
(Fig. 2C) among those genes whose expression was
upregulated with degarelix treatment (Fig. 2C).
IHC demonstrated expression of ESR1 by stromal
cells but not epithelial cells (benign or malignant) in
untreated samples, but 24% of degarelix-treated cancers
stained positive for ESR1 in malignant epithelia compared
[(Fig._2)TD$FIG]
Fig. 2 – ESR1 is upregulated in response to degarelix treatment. (A) Dot plots to show mRNA expression levels of ESR1 in untreated and degarelix-
treated prostate cancer (PCa) samples by expression array. (Bi) Using the Gene Set Enrichment Analysis (GSEA) to examine the distribution of known
genes with the ESR1 binding motif, shown within their promoter regions, we found that these genes were enriched among genes that degarelix
treatment upregulated when they were ranked by their statistical significance. The ESR1 binding motif analysed was described previously [7].
(Bii) This ESR1 binding motif closely matches the validated, experimentally derived ESR1 binding motif [10] shown here. (C) GSEA demonstrates
enrichment of factors known to be involved with ESR1 signalling (from the National Cancer Institute BIOCARTA curated database) among genes
differentially expressed in response to degarelix ranked by statistical significance. For this analysis, the degree to which the genes were enriched is
defined by the running sum statistic called the normalised enrichment score, which was 2.036 (false discovery rate q-value of 0.027; p = 0.024).
(D) Representative images of PCa samples stained by immunohistochemistry (IHC) for ESR1 in untreated and degarelix-treated patients with intense
nuclear staining seen in the malignant epithelia of the treated but not the untreated samples. Scale bars = 250 mm. (E) IHC ESR1 staining was
increased in treated (+) compared with untreated (S) PCa samples in malignant epithelia but not cancer-associated stroma or benign epithelia
(samples in triplicate; sample sizes [n] indicate the number of subjects [20 or 27] times 3 minus missing or damaged samples on the human tissue
microarray; staining intensity 0 [none] to 3 [strong]). Mean intensities from replicate samples for each patient were used to calculate statistical
significance when comparing treated and untreated groups (Mann-Whitney test). (F) Graph shows correlation between intensity of staining by IHC
for ESR1 and Ki-67. Spearman’s r correlation coefficient of 0.338 (p = 0.041).
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with 8% of untreated samples (Fig. 2E). Despite an overall
decrease in the expression of the proliferation marker
Ki-67 in malignant glands following degarelix treatment
(Fig. 1B and 1C); in those glands with increased nuclear
ESR1 staining, proliferation was upregulated (Fig. 2F).
3. Discussion
In addition to identifying a large number of AR-regulated
genes, we have confirmed AR regulation of three genes
(RAB27A, FAM129, and KIAA0101) not proven to be AR
regulated in vivo as well as AMACR, for which data were
conflicting. ESR1 is essential for prostate carcinogenesis and
implicated in PCa growth control [8]. Polymorphism of ESR1
is associated with PCa prognosis [9].
We observed rapid upregulation of ESR1 expression with
castration (Fig. 2A). Increased ESR1 mRNA expression
following prolonged castration using LHRH analogues has
been observed [2,3]. Upregulation of ESR1 expression may
represent an intrinsicmechanism bywhich somemalignant
prostate epithelial cells proliferate despite castration.
Author contributions: Greg L. Shaw had full access to all the data in the
study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Study concept and design: Shaw, Whitaker, Corcoran, Mills, Neal, Massie,
Lynch, Nelson.
Acquisition of data: Shaw, Corcoran, Luxton, Kay, Miller, Warren, Arlt,
Taylor, Shah, Ross-Adams.
Analysis and interpretation of data: Shaw, Dunning, Lamb, Eldridge,
Russell, Ramos-Montoya.
Drafting of the manuscript: Shaw, Whitaker, Lamb, Nelson, Russell.
Critical revision of the manuscript for important intellectual content: Shaw,
Mills, Neal, Massie.
Statistical analysis: None.
Obtaining funding: Shaw, Neal.
Administrative, technical, or material support: None.
Supervision: Mills, Neal.
Other (specify): None.
Financial disclosures: Greg L. Shaw certiﬁes that all conﬂicts of interest,
including speciﬁc ﬁnancial interests and relationships and afﬁliations
relevant to the subject matter or materials discussed in the manuscript
(eg, employment/afﬁliation, grants or funding, consultancies, honoraria,
stock ownership or options, expert testimony, royalties, or patents ﬁled,
received, or pending), are the following: None.
Funding/Support and role of the sponsor: The Academy of Medical
Sciences, the National Institute for Health Research, Cancer Research UK,
andNationalCancerResearchprovided funding for thedesignandconduct
of the study as well as the collection, analysis, and interpretation of data.
Acknowledgments: The authors thank CRUK; the NIHR; the Academy
of Medical Sciences (RG:63397); the National Cancer Research
Prostate Cancer: Mechanisms of Progression and Treatment (ProMPT)
collaborative (G0500966/75466); Hutchison Whampoa Limited; the
Human Research Tissue Bank (Addenbrooke’s Hospital, supported by
the NIHR Cambridge BRC); and Cancer Research UK. We would like to
thank those men with prostate cancer and the subjects who have
donated their time and their samples to the Cambridge Biorepository
that were used in this research. We also acknowledge the support of
the research staff in S4, who so carefully curated the samples and the
follow-up data (Jo Burge, Marie Corcoran, Anne George, and Sara
Stearn).
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.
eururo.2015.10.042.
References
[1] Siegel RL,Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin
2015;65:5–29.
[2] Lehmusvaara S, Erkkila T, Urbanucci A, et al. Chemical castration
and anti-androgens induce differential gene expression in prostate
cancer. J Pathol 2012;227:336–45.
[3] Rajan P, Sudbery IM, Villasevil ME, et al. Next-generation sequenc-
ing of advanced prostate cancer treated with androgen-deprivation
therapy. Eur Urol 2014;66:32–9.
[4] D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical
outcome after radical prostatectomy, external beam radiation ther-
apy, or interstitial radiation therapy for clinically localized prostate
cancer. JAMA 1998;280:969–74.
[5] Warren AY, Whitaker HC, Haynes B, et al. Method for sampling
tissue for research which preserves pathological data in radical
prostatectomy. Prostate 2013;73:194–202.
[6] Sharma NL, Massie CE, Ramos-Montoya A, et al. The androgen
receptor induces a distinct transcriptional program in castration-
resistant prostate cancer in man. Cancer Cell 2013;23:35–47.
[7] Sandelin A, WassermanWW. Prediction of nuclear hormone recep-
tor response elements. Mol Endocrinol 2005;19:595–606.
[8] RickeWA,McPherson SJ, Bianco JJ, Cunha GR,Wang Y, Risbridger GP.
Prostatic hormonal carcinogenesis is mediated by in situ estrogen
production and estrogen receptor alpha signaling. FASEB J 2008;22:
1512–20.
[9] Gu Z, Wang G, Chen W. Estrogen receptor alpha gene polymor-
phisms and risk of prostate cancer: a meta-analysis involving
18 studies. Tumour Biol 2014;35:5921–30.
[10] Welboren WJ, van Driel MA, Janssen-Megens EM, et al. ChIP-Seq of
ERalpha and RNA polymerase II deﬁnes genes differentially
responding to ligands. EMBO J 2009;28:1418–28.
E U RO P E AN URO LOGY 7 0 ( 2 0 1 6 ) 2 1 4 – 2 1 8218
